



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Philippe G. Nantermet et al.

Serial No.:

10/573,232

Case No.: 21546YP

US Nat'l Filing Date:

March 23, 2006

Int'l Appl'n No.

PCT/US2004/032009

Int'l Filing Date:

29 September 2004

For:

BENZYLETHER AND BENZYLAMINO BETA-SECRETASE

INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S

DISEASE

MAIL STOP PCT Commissioner for Patents P.O. BOX 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

I hereby certify that this correspondence is being deposited with the United States Postal Services as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on the date appearing

Below.

MERCK/& CO., INC.

Date Jul 21 XXX

المر_{وب} (

Int'l Appl'n No.:

PCT/GB2004/032009 21546YP

Case No.: Page

2

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application. Accordingly, it is believed that no fee is due. Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

Bv ∫

ohn C. Todaro, Reg. No. 36,036

Attorney for Applicant

MERCK & CO., Inc.

P.O. Box 2000

Rahway, New Jersey 07065-0907

(732) 594-0125

Date: June 21, 2006

	COMPLETE IF KNOWN	
Application Number	10/573,232	
Filing Date	March 23, 2006	
First Named Inventor	Philippe G. Nantermet	
Group Art Unit	To Be Assigned	
Examiner Name	To Be Assigned	
Attorney Docket Number	21546YP	
	Application Number Filing Date First Named Inventor Group Art Unit Examiner Name	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Docum		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
	-					
,,						
		1				

			FORE	GN PATEN	T DOCUMENTS	
Examiner Initials*			Foreign Patent Document Kind Code (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	A		WO 2005/005374	PCT	Sunesis Pharmaceuticals, Inc.	01/20/2005
	В		WO 03/106405	PCT	Sunesis Pharmaceuticals, Inc.	12/24/2003
1						
4						
Examin Signatu					Date Considered	

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.